On Friday, Pfizer Inc (NYSE:PFE) released longer-term follow-up results from the Phase 3 CROWN trial evaluating Lorbrena (lorlatinib) available in Europe as Lorviqua versus Xalkori (crizotinib) in people with previously untreated, anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Also Read: Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac. After five years of median follow-up, median progression-free survival (PFS) based on investigator assessment was not reached with Lorbrena, with an observed Hazard Ratio (HR) of 0.19, representing an 81% reduction in disease progression or death rate compared to ...